University of Sydney (USYD)

Hematological immune related adverse events after treatment with immune checkpoint inhibitors (2021) Kramer R, Zaremba A, Moreira A, Ugurel S, Johnson DB, Hassel JC, Salzmann M, et al. Journal article Sociodemographic correlates of physical activity and sport among adults in Germany: 1997–2018 (2021) Abu-Omar K, Messing S, Sarshar M, Gelius P, Ferschl S, Finger J, Bauman A Journal article New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia (2021) Trpkov K, Hes O, Williamson SR, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, et al. Journal article Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk (2021) Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, Michailidou K, et al. Journal article Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia (2021) Trpkov K, Williamson SR, Gill AJ, Adeniran AJ, Agaimy A, Alaghehbandan R, Amin MB, et al. Journal article Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) Rogiers A, Da Silva IP, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, et al. Journal article Second-Harmonic Generation in Directly-Grown MoS2 Monolayers on Exposed-Core Fibers (2021) Ngo GQ, Najafidehaghani E, Gan Z, Khazaee S, George A, Peschel U, Tuniz A, et al. Conference contribution Deep Learning-Empowered Predictive Beamforming for IRS-Assisted Multi-User Communications (2021) Liu C, Liu X, Wei Z, Hu S, Ng DWK, Yuan J Conference contribution Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article